Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025Business Wire • 05/01/25
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged TodayThe Motley Fool • 04/25/25
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in ChinaBusiness Wire • 04/25/25
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025Business Wire • 04/24/25
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in ChinaBusiness Wire • 04/23/25
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing CompetitionSeeking Alpha • 04/14/25
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the MarketsThe Motley Fool • 04/10/25
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a DecadeThe Motley Fool • 04/06/25
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged TodayThe Motley Fool • 03/31/25
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial OfficerBusiness Wire • 03/17/25
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This YearThe Motley Fool • 03/13/25